CRNX
Price
$55.38
Change
+$0.75 (+1.37%)
Updated
Dec 17, 04:59 PM (EDT)
90 days until earnings call
XENE
Price
$40.87
Change
-$0.41 (-0.99%)
Updated
Dec 18, 11:15 AM (EDT)
70 days until earnings call
Ad is loading...

CRNX vs XENE

Header iconCRNX vs XENE Comparison
Open Charts CRNX vs XENEBanner chart's image
Crinetics Pharmaceuticals
Price$55.38
Change+$0.75 (+1.37%)
Volume$8.14K
CapitalizationN/A
Xenon Pharmaceuticals
Price$40.87
Change-$0.41 (-0.99%)
Volume$100
CapitalizationN/A
CRNX vs XENE Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. XENE commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and XENE is a Buy.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (CRNX: $55.37 vs. XENE: $41.28)
Brand notoriety: CRNX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 154% vs. XENE: 68%
Market capitalization -- CRNX: $5.13B vs. XENE: $3.15B
CRNX [@Biotechnology] is valued at $5.13B. XENE’s [@Biotechnology] market capitalization is $3.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • CRNX’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 6 bearish.
  • XENE’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, XENE is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -3.15% price change this week, while XENE (@Biotechnology) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.83%. For the same industry, the average monthly price growth was +1.09%, and the average quarterly price growth was +9.71%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 18, 2025.

XENE is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-4.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($5.14B) has a higher market cap than XENE($3.15B). CRNX YTD gains are higher at: 55.621 vs. XENE (-10.378). XENE has higher annual earnings (EBITDA): -252.74M vs. CRNX (-304.51M). CRNX has more cash in the bank: 863M vs. XENE (654M). XENE has less debt than CRNX: XENE (9.79M) vs CRNX (52.5M). CRNX has higher revenues than XENE: CRNX (1.04M) vs XENE (0).
CRNXXENECRNX / XENE
Capitalization5.14B3.15B163%
EBITDA-304.51M-252.74M120%
Gain YTD55.621-10.378-536%
P/E RatioN/AN/A-
Revenue1.04M0-
Total Cash863M654M132%
Total Debt52.5M9.79M536%
FUNDAMENTALS RATINGS
CRNX vs XENE: Fundamental Ratings
CRNX
XENE
OUTLOOK RATING
1..100
1871
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
912
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
4450
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
385

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (92) in the Pharmaceuticals Major industry is in the same range as XENE (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to XENE’s over the last 12 months.

CRNX's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is in the same range as XENE (12) in the Biotechnology industry. This means that CRNX’s stock grew similarly to XENE’s over the last 12 months.

XENE's SMR Rating (94) in the Biotechnology industry is in the same range as CRNX (96) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as XENE (50) in the Biotechnology industry. This means that CRNX’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXXENE
RSI
ODDS (%)
Bearish Trend 7 days ago
86%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 9 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OCEN21.28N/A
N/A
NYLI Clean Oceans ETF
PLTM9.08N/A
-0.05%
GraniteShares Platinum Trust
PYLD26.11-0.02
-0.08%
PIMCO Multisector Bond Active ETF
IGOV39.45-0.11
-0.28%
iShares International Treasury Bond ETF
FVC38.04-0.36
-0.94%
First Trust Dorsey Wright Dynamic Foc 5

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XENE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.35%
XENE - CRNX
47%
Loosely correlated
-0.07%
ARWR - CRNX
47%
Loosely correlated
-0.45%
PGEN - CRNX
44%
Loosely correlated
+2.46%
RARE - CRNX
44%
Loosely correlated
-0.99%
ELVN - CRNX
44%
Loosely correlated
+3.48%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with PLRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-0.07%
PLRX - XENE
48%
Loosely correlated
+4.74%
PGEN - XENE
47%
Loosely correlated
+2.46%
RCKT - XENE
47%
Loosely correlated
+1.36%
CRNX - XENE
46%
Loosely correlated
+1.35%
KYMR - XENE
44%
Loosely correlated
-1.76%
More